Cancer gets all the headlines, but autoimmune diseases are exploding in China. Rheumatoid arthritis, psoriasis, Crohn’s — they’re no longer “Western diseases.” The China antibodies market research study shows that autoimmune applications are the fastest‑growing segment, with a CAGR above 15%. Why? Better diagnosis (more rheumatologists), rising affluence (people can afford biologics), and environmental triggers (pollution linked to autoimmunity).

Blockbuster drugs like Humira (adalimumab) and Stelara (ustekinumab) are now off‑patent, and Chinese biosimilars are flooding the market. The China antibodies market trends highlight that the government’s NRDL now covers several autoimmune antibodies, making them affordable for the middle class. That’s a huge shift from a decade ago, when these drugs were luxury items.

But there’s a dark side: overprescription. Some clinics push expensive biologics for mild cases, ignoring first‑line treatments like methotrexate. That’s both a health and economic concern. The solution? Better doctor education and treatment guidelines.

The bottom line: China’s autoimmune antibody market is a sleeping giant that’s waking up. For pharma companies, it’s a massive opportunity. For patients, it’s hope — but use it wisely.